The tests detects a protein called troponin, which is released into the blood when the heart muscle is damaged — by a heart attack.
But while the conventional troponin test takes three hours, the high-sensitivity version can give results in less than an hour.
The hope with the new test is to more quickly rule out a heart attack in those patients, Vigen said.
“If we can give patients and families an answer sooner, that would be a good thing,” said Vigen, a cardiologist at the University of Texas Southwestern Medical Center.
High-sensitivity troponin tests have been available in Europe and elsewhere for years. But the first such test in the United States, marketed by Roche Diagnostics, was just approved last year.
In the new study, Vigen’s team gauged how well that blood test is performing among patients at their Dallas hospital system. It used both the standard test and the high-sensitivity version to measure troponin levels in 536 patients who arrived at the emergency department with chest pain, shortness of breath or other possible heart attack symptoms.
Overall, the study found, that initial high-sensitivity test ruled out a heart attack in 30 percent of patients. The second, done at the one-hour mark, put another 25 percent in the clear.
By the three-hour point, the high-sensitivity test had ruled out a heart attack in 84 percent of patients — versus 80 percent with the conventional test.
Dr. Christopher Granger is a cardiologist at Duke University in Durham, N.C. He also serves on the American College of Cardiology/American Heart Association guideline committee for heart attack care.
Granger said only a limited number of U.S. hospitals now have the high-sensitivity troponin test.
“But I expect it will be rapidly adopted over the next few years,” said Granger, who was not involved in the study.
Evidence from Europe already shows the benefits of high-sensitivity tests, he noted. “It has substantially improved the efficiency of care,” Granger said.
The test can help speed a heart attack diagnosis. But the biggest advantage, according to Granger, is that it more quickly rules out a heart attack in the many patients who are not having one.
“And that’s important to patients and their families,” he said.
The study was published online Aug. 6 in the journal Circulation. Some of its co-authors have financial relationships with Roche.